Peers

Sudarshan Pharma Industries Ltd. exhibits moderate growth and profitability metrics compared to its peers in the pharmaceuticals sector. While its revenue growth and profitability margins are lower than the sector leaders, its valuation metrics suggest it may be undervalued relative to its earnings potential, making it a potential candidate for investors looking for growth opportunities.

• • Sudarshan Pharma's revenue growth is 8.95% YoY, lower than industry leaders like Mankind Pharma with 18.12%.
• • It has a PE ratio of 49.67 which is higher than some peers indicating a potentially high valuation.
• • ROE at 10.77% is below the average in the sector, indicating room for improvement in profitability.
• • The debt-equity ratio of 0.94 suggests moderate leverage compared to peers.
• • Overall, Sudarshan Pharma is positioned as a growth opportunity but may have to improve operational efficiency.

• • Mankind Pharma Ltd.: Highest revenue growth (18.12% YoY) and strong profitability metrics with ROE at 23.15%.
• • Dr. Reddy's Laboratories Ltd.: Strong profitability with ROE at 21.76% and a low PE ratio of 15.50, indicating good value.
• • Cipla Ltd.: Good balance of growth (13.28% YoY) and low PE (23.73) indicating strong fundamentals.
• • Sun Pharmaceutical Industries Ltd.: Highest ROE at 16.13% and good EPS growth, but high PE suggests overvaluation.